1Wall ME,Wani MC,Cook CE.et al.Antitumor agent 1.the isolation and structure of camptothecin,a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate.J Am Chem Soc,1966,88 (16):3888-3890
3Vishnuvajjala BR,Garzon-Aburbeh A.Water soluble prodrugs of camptothecin.US Patent 4943579,1990
4Cao Z,Harris N,Kozielski A.et al.Alkyl ester of camptothecin and 9-nitrocamptothecin:synthesis,in vitro pharmacokinetics,toxicity,and antitumor activity.J Med Chem,1998,41:31-37
5Cao Z,Giovanella BC.Aromatic esters of camptothecins and methods to treat cancers.US Patent 6228855,2001
6Yang LX,Pan XD,Wang HJ.Novel camptothecin derivatives.Part 1:oxyalkanoid acid esters of camptothecin and their in vitro and in vivo antitumor activity.Bioorg Med Chem Lett,2002,12 (9):1241-1244
8Pan XD,Han R,Sun PY.Regioselective synthesis and cytotoxicities of camptothecin derivatives modified at 7-,10-and 20-positions.Bioorg Med Chem Lett,2003,13 (21):3739-3741
10Conover CD,Greenwald RB,Pendri A,et al.Camptothecin delivery systems:the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol create prodrugs.Anti-cancer Drug Des,1999,14:499-506
二级参考文献28
1[1]Wall ME, Wani MC, Cook CE, et al. Antitumor agent I. The isolation and structure of Camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata [J]. J Amer Chem Soc, 1966,88(16):3888-3890.
2[2]O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration [J]. Eur J Cancer, 1998,34(10):1500-1508.
3[3]Liu LF, Desai SD, Li TK, et al. Mechanism of action of camptothecin [J]. Ann N Y Acad Sci, 2000,922:1-10.
4[4]Slichenmyer WJ, Rowinsky EK, Donehower RC. The current status of camptothecin analogues as antitumor agents [J]. J Nat Cancer Inst, 85(4):271-291.
5[5]Saijo N. Clinical trials of irinotecan hydrochloride in Japan [J]. Ann N Y Acad Sci, 1996,803:292-305.
6[6]Broom C. Clinical studies of Topotecan [J]. Ann N Y Acad Sci, 1996,803:264-271.
7[7]Mitsui I, Kumazawa E, Hirota Y, et al. A new water-soluble camptothecin derivative, DX-8 951 f, exhibits potent antitumor activity against human tumors in vitro and in vivo [J]. Jpn J Cancer Res, 1995,86:(8)776-782.
8[8]Luzzio MJ, Besterman JM, Emerson DL, et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I [J]. J Med Chem, 1995,38(3):395-401.
9[9]Lee JH, Lee JM, Lim KH, et al. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative [J]. Ann NY Acad Sci, 2000,922:324-325.
10[10]Verschraegen CF, Gupta E, Loyer E et al. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin patents with refractory epithelial ovarian, tubal or peritoneal cancer [J]. Anticancer Drugs, 1999,10(4):375-383.
